Skip to content

Vor Biopharma VOR Operating lease liabilities

Operating lease liabilities at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
Immunome logo
ImmunomeIMNM
TG Therapeutics logo
TG TherapeuticsTGTX
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's operating lease liabilities?
Vor Biopharma (VOR) reported operating lease liabilities of -$61K in Q1 2026.
How has Vor Biopharma's operating lease liabilities changed year-over-year?
Vor Biopharma's operating lease liabilities increased by 94.2% year-over-year, from -$1.05M to -$61K.
What is the long-term trend for Vor Biopharma's operating lease liabilities?
Over 4 years (2021 to 2025), Vor Biopharma's operating lease liabilities has grown at a -1.5% compound annual growth rate (CAGR), from -$2.56M to -$2.41M.